ArticleFrontiers in immunology2026
Multi-omic profiling converges on proteasome subunits PSMA7/PSMB2 as targets of the sepsis-protective agent Handelin.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sepsis is a life-threatening systemic inflammatory syndrome with limited targeted therapeutic options. Handelin, a natural compound derived from Chrysanthemum indicum, exhibits anti-inflammatory activity, yet its direct targets and protective mechanisms in sepsis remain unclear. Methods: We established a lipopolysaccharide (LPS)-induced sepsis-like model in zebrafish larvae to evaluate the protective effects of Handelin. Survival, locomotor behavior, macrophage recruitment, and systemic reactive oxygen species (ROS) levels were assessed. To identify direct protein targets, we performed drug affinity responsive target stability profiling using data-independent acquisition mass spectrometry (DIA-CETSA) in macrophages. Clinical relevance was examined via 4D-DIA proteomics of plasma from a sepsis patient cohort and meta-analysis of public transcriptomic datasets. Molecular docking and dynamics simulations were used to characterize binding interactions. Results: Handelin significantly improved survival, restored locomotor activity, suppressed macrophage aggregation, and reduced ROS in zebrafish. DIA-CETSA revealed that Handelin specifically stabilized multiple core subunits of the 26S proteasome, most notably PSMA7 and PSMB2. In sepsis patients, higher plasma levels of PSMA7 and PSMB2 were associated with increased 90-day mortality and positively correlated with markers of liver injury and SOFA scores. Transcriptomic meta-analysis across 10 independent cohorts revealed that PSMA7 expression was significantly higher in non-survivors than survivors, while PSMB2 showed a similar trend that was marginally significant and sensitive to cohort composition. These findings highlight the complex relationship between transcriptional regulation and clinical outcomes in sepsis, with favorable predicted binding affinities. Discussion: This study suggests that the protective effect of Handelin in sepsis may be associated with its stabilization of the core proteasome subunits PSMA7 and PSMB2. These findings provide new pharmacological insights into the potential anti-septic application of Handelin and propose a novel strategic direction for the treatment of sepsis through precise modulation of proteasome function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.